FDA Orders Blindness Risk Warning on GLP-1 Weight-Loss Drugs Including Ozempic and Mounjaro
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
On Monday the FDA required all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, Zepbound, and Soliqua, to warn of NAION, a rare condition that can cause sudden painless vision loss and permanent blindness. The step follows a 2024 JAMA Ophthalmology study linking GLP-1 use to higher NAION risk; there is no treatment to reverse the vision loss.
Continue in the app — vote & join in ➔Source: The Guardian World · via ahirlevel.hu